MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Solid Tumor|Advanced Cancer|Metastatic Cancer|Non Small Cell Lung Cancer|Cutaneous Squamous Cell Carcinoma|Merkel Cell Carcinoma|Melanoma|Pancreatic Cancer|Triple Negative Breast Cancer|Head and Neck Cancer
Interventions: BIOLOGICAL: MEM-288 Intratumoral Injection|BIOLOGICAL: Nivolumab
Sponsor: Memgen, Inc.
Collaborators: Duke Cancer Institute|H. Lee Moffitt Cancer Center and Research Institute